BiomX Inc. (NASDAQ:PHGE) has received an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Analysts have set a 1 year consensus price target of $28.00 for the company, according to Zacks. Zacks has also assigned BiomX an industry rank of 143 out of 255 based on the ratings given to related companies.
Shares of NASDAQ:PHGE traded up $0.21 during midday trading on Friday, reaching $9.25. The company had a trading volume of 1,718 shares, compared to its average volume of 21,488. BiomX has a one year low of $6.13 and a one year high of $11.90.
BiomX Company Profile
BiomX Ltd discovers and develops microbiome-based therapeutics to prevent and treat cancer and inflammatory bowel disease (IBD). It uses its 3-tier microbiome modulation platform and applies it to identify target bacteria causing microbiome dysbiosis; modulates the microbiome through adding or eradicating bacteria; and engages in pre-clinical/clinical drug development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.